INSIGHTA ▶

Saving Lives Through the Power of Early Detection

Prenetics™

Disclaimer

INSIGHTA

Presentation Participants

Dennis Lo
Chairman of the Board & Co-Founder

Danny Yeung
CEO

INSIGHTA

Prenetics and Globally Renowned Scientist Prof. Dennis Lo Establish US$200m Joint Venture for Breakthrough Multi-Cancer Early Detection

World Class Science and IPs, led by **Professor Dennis Lo**, one of the world's most influential and highly respected pioneers in liquid biopsy, considered the father of
Non-Invasive Prenatal Testing.

Prenetics contribution is **US$100M in consideration** (US$80M in cash and US$20M in Prenetics shares). Capital will be directly used to accelerate clinical trials and commercialization for the **Presight** test, the 1st test by Insighta.

Strong and proven management team led by Prenetics **CEO – Danny Yeung.** Demonstrated history of success.

INSIGHTA

Led by Renowned Scientist Prof. Dennis Lo, the Father of Non-Invasive Prenatal Testing (NIPT)

Prof. Dennis Lo

- Associate Dean (Research) of the Faculty of Medicine of CUHK
- Director of the Li Ka Shing Institute of Health Sciences, the Li Ka Shing Professor of Medicine and Professor of Chemical Pathology of CUHK
- Founding Scientific Director of Centre for Novostics, funded by the InnoHK Initiative of the Innovation and Technology Commission of the Hong Kong SAR Government

- Introduced ground breaking NIPT technology in 2011, now screening over 10 million expectant mothers annually across 90+ countries.
- Global market value of NIPT stands at US$7.3bn, increasing to US$13.1bn by 2027.[1]
- Honored with life sciences most prestigious awards: Fellow of the Royal Society (2011), Royal Medal and Breakthrough Prize (2021), and the distinguished Lasker Award (2022).
- Co-founded Cirina, acquired by GRAIL for US$300m in 2017, subsequently purchased by Illumina for US$7.1bn.
- Provided intellectual property, R&D leadership, and science oversight for the breakthrough multi-cancer early detection technology "FRAGMA," published in 2022[2].

1. https://www.annualreviews.org/doi/10.1146/annurev-genom-083118-015053
2. https://www.pnas.org/doi/10.1073/pnas.2209852119

INSIGHTA▸

INSIGHTA Board of Directors

Prof. Dennis Lo
Chairman of the Board & Co-Founder

Danny Yeung
CEO

Anand Madduri
Founder and CIO of ApaH Capital

Prof. Allen Chan
Co-Founder

Ben Cheng
MD of C Capital

Prof. Tony Mok
Chairman, Dept of Clinical Oncology;
Li Shu Fan Prof. of Oncology CUHK

INSIGHTA▶

Our breakthrough technology **detects cancers at the early stages,** significantly improving the chances of treatment and ultimately saving lives.

Cancer Kills 10M People Worldwide Annually

Oceania
69,354 (0.7%)

North America
699,274 (7%)

Africa
711,429 (7.1%)

Latin America and
the Caribbean
713,414 (7.2%)

TOTAL DEATHS
9,958,133

Europe
1,955,231 (19.6%)

Asia
5,809,431 (58.3%)

6M Deaths in Asia.
Every Year.

Data source: Globocan 2020

8

INSIGHTA▸

Early Detection Provides Patients with the Best Possible Outcomes and in Saving Lives

5-Year global survival rate at various stages of diagnosis

- 🟠 Ovarian Cancer
- 🟢 Prostate Cancer
- 🟢 Pancreatic Cancer
- 🔴 Liver Cancer
- 🔵 Lung Cancer

89% Survival — High 5-year cancer-specific survival when diagnosed early

21% Survival — Low 5-year cancer-specific survival when diagnosed late

INSIGHTA

Early Detection Can Potentially Benefit 1 billion+ People. Annually.

Population Group	Estimated Number of People (as of 2021)
Total global population	7.8 billion
People age of 40+ globally	2.03 billion
Total population in Asia	4.7 billion
People age of 40+ in Asia	1.22 billion
Total population in China	1.41 billion
People age of 40+ in China	366 million

Note: the median age of cancer diagnosis is 66 years of age according to data from the American Cancer Society. This suggests that the population most likely to benefit from early detection is aged 40 and above

INSIGHTA▸

Lung Cancer, #1 Deadliest Cancer in China

High Incidence

- ~ 135 million people at-risk, whom are aged 50-80 with smoking history
- ~ 900,000 lung cancer cases diagnosed in China in 2019

High Mortalities and Late Detection

- ~47% of diagnosed cases of lung cancer are in stage 3 and 4 with 6% survival rate
- Only ~23% of diagnosed cases of lung cancer are in stage 1 and 2
- Lung cancer was by far the most lethal cancer type in China, killing more than 700,000 people in 2020

Current Screening is Unsatisfactory

- Current globally-accepted guidelines recommend annual low-dose helical CT scan screening for high-risk individuals
- Low ~0.4% screening rate for lung cancer in China

Note: population and prevalence data based on multiple sources including from WHO, IARC, WCLC, national health departments and industries, and research institutions

INSIGHTA▶

Liver Cancer, the 2nd Deadliest Cancer in China

High Incidence
- ~ 85 million people living with chronic hepatitis B infection
- ~ 404,000 newly diagnosed cases of liver cancer in China in 2020

High Mortalities and Late Detection
- ~ 56% of diagnosed cases of liver cancer are in stages 3 and 4
- Only ~ 17.5 % of diagnosed cases of liver cancer are in stage 1
- ~ 372,000 deaths of liver cancer in China in 2020

Current Screening is Unsatisfactory
- Ultrasound, AFP and CT is current standard of care for liver cancer diagnosis
- Sensitivity ranges between ~ 45% for Ultrasound and ~ 63% for ultrasound + AFP

Note: population and prevalence data based on multiple sources including from WHO, IARC, national health departments and industries, and research institutions

INSIGHTA

At-Risk Liver and Lung Cancer Population in Asia is 400M Compared to 24M in USA

	Combined 400M people at-risk						24M in USA
	China	India	Indonesia	Vietnam	Philippines	Thailand	USA
At-Risk Screening Population (Millions)	**220** 135M Lung 85M Liver	**112** 72M Lung 40M Liver	**34** 22M Lung 12M Liver	**15** 7M Lung 8M Liver	**11** 4M Lung 7M Liver	**8** 5M Lung 3M Liver	**24** 13M Lung 11M Liver
Indications	HBV Carriers / Aged 50+ Smokers	HBV Carriers / Aged 50+ Smokers	HBV Carriers / Aged 50+ Smokers	HBV Carriers / Aged 50+ Smokers	HBV Carriers / Aged 50+ Smokers	HBV Carriers / Aged 50+ Smokers	HCV Carriers & NASH Aged 50+ Smokers

Note: population and prevalence data based on multiple sources including from WHO, IARC, national health departments and industries, and research institutions

INSIGHTA

INSIGHTA

The Science

Transforming Early Detection with World-Class Science

Take2 | CU Medicine – Faculty of Medicine, The Chinese University of Hong Kong | ctDNA – EB DNA | Prospective 20,174 Clinical Trial

+

INSIGHTA | | cf-DNA – FRAGMA | Development & Validation

87 Patent families

690+ Publications

Led by Prof. Dennis Lo and Prof. Allen Chan, pioneers in liquid biopsy.

INSIGHTA

Large-scale Proven Accuracy for Liquid Biopsy for Nasopharyngeal Cancer Screening

20,174
SCREENED

34
CANCER POSITIVE

97.1%
SENSITIVITY

98.6%
SPECIFICITY

Table 2. Sensitivity and Specificity of the Two-Stage Screening Protocol for the Detection of Nasopharyngeal Carcinoma.*

Finding	Screen-Positive (N = 308)†	Screen-Negative (N = 19,865)
Confirmed nasopharyngeal carcinoma by the screening protocol or nasopharyngeal carcinoma reported to have developed within 1 yr — no.	34	1
No nasopharyngeal carcinoma within 1 yr after screening — no.	274	19,864
Sensitivity — % (95% CI)	97.1 (95.5–98.7)	
Specificity — % (95% CI)	98.6 (98.6–98.7)	
Positive predictive value — % (95% CI)	11.0 (10.7–11.3)	
Negative predictive value — % (95% CI)	99.995 (99.99–100.00)	
Proportion of stage I/II disease in the 34 cases of nasopharyngeal carcinoma identified by screening — % (95% CI)	70.6 (69.6–72.5)	

Source: https://www.nejm.org/doi/full/10.1056/nejmoa1701717

INSIGHTA

Quantum Leap FRAGMA Liquid Biopsy Platform

Proprietary cfDNA technology

Epigenetics is the modification of DNA that affect its behavior without changing the DNA sequence.

Fragmentation pattern of plasma DNA can be used as an epigenetics-based multi-cancer test.

Simple analytic workflow

Rapid turn-around time

Expandable to other cancers

Low cost

INSIGHTA

FRAGMA Science

Background

The detection of methylation aberrations in plasma DNA provides a non-invasive means for the detection of a wide variety of cancers. FRAGMA is a new technology which allows the determination of DNA methylation status without the use of bisulfite treatment, enzymatic conversion or 3rd generation sequencing.

Applications of FRAGMA for Liver Cancer (HCC)

- 20 patients had early-stage HCC
- 7 patients had intermediate stage HCC

- 7 patients had advanced HCC
- 38 healthy subjects and 17 hepatitis B carriers

Source: https://www.pnas.org/doi/10.1073/pnas.2209852119

INSIGHTA

Applications of FRAGMA for Colorectal Cancer

- 11 patients had colorectal cancer
- 8 healthy subjects

CRC vs. Control: AUC = 1.0

1.0
AUC

Source: https://www.pnas.org/doi/10.1073/pnas.2209852119

20

INSIGHTA

Applications of FRAGMA for Lung Cancer

- 10 patients had lung cancer
- 8 healthy subjects

INSIGHTA

Applications of FRAGMA for Bladder Cancer by Urine

- 19 low grade non-muscle invasive bladder cancer
- 18 high grade non-muscle invasive bladder cancer
- 9 muscle invasive bladder cancer

INSIGHTA

Summary of FRAGMA Technology

FRAGMA provides an accurate and low cost method for studying the genomewide methylation profile of circulating DNA.

As DNA methylation changes are hallmarks for a wide variety of cancers, this can be potentially applied to a multi-cancer early detection test.

1 Accurate and early detection of HCC (Liver Cancer) with shallow-depth sequencing

2 Initial studies has also shown it is applicable for **early detection for lung and colorectal cancer**

3 Urine DNA has shown to be valuable for the **early detection of urogenital cancers**

4 **Versatile technology** can be potentially applied to a Multi-cancer early detection test

5 **Low cost,** enabling accessibility of early detection cancer to a much wider population than current testing methods

INSIGHTA

INSIGHTA▷

Introducing Presight.
Our 1st Test

Presight Liver Cancer Trial Details

89 Participants

Participants with and without cancer
Completed

500 Participants

Participants with and without cancer
Almost Completed

5,000 Participants

Participants with and without cancer
Not Yet Enrolled

Development & Validation

Case Control

Prospective Multi-Country Study

INSIGHTA

Strong Product Pipeline Backed by World-Class Science

Product	Indication	Early Stage Development	Case Control Study	Prospective Trial	Regulatory Approval
Presight Liver	Liver Cancer Screening	████████████████			
Presight Bladder	Bladder Cancer Screening	██████			
Presight Lung	Lung Cancer Screening	██████			
Presight One MCED	10+ Multi-Cancer Screening	███			

INSIGHTA▶

Key Commercial Roadmap for the Next 5 Years

Product	Indication	2024	2025	2026	2027	2028
Presight Liver	Liver Cancer Screening			Launch in China / HK	Launch in Rest of Asia	
Presight Bladder	Bladder Cancer Screening			Launch in China / HK	Launch in Rest of Asia	
Presight Lung	Lung Cancer Screening				Launch in China / HK	Launch in Rest of Asia
Presight One MCED	10+ Multi-Cancer Screening					Launch in China / HK	Launch in Rest of Asia

INSIGHTA

A US$6B Screening Opportunity in 2030 in Asia. Annually.

Presight Liver	Liver Cancer Screening
Presight Bladder	Bladder Cancer Screening
Presight Lung	Lung Cancer Screening
Presight One MCED	10+ Multi-Cancer Screening

US$6B sales potential in 2030 with robust margins
- ✔ 30m+ annual test population in liver and lung cancer (400m at-risk)
- ✔ Additional cancers and MCED creates further upside
- ✔ Targeting 70% gross margins at scale

High sensitivity and low cost screening test
- ✔ Target of 90% or greater sensitivity
- ✔ Target of less than US$200 for end user price

US$80M cash
- ✔ Strong cash position allows ability to fund clinical trials without further funding
- ✔ Allows for commercialization
- ✔ Cash also allows research and development of new technologies, and generation of IPs

INSIGHTA

By year 2035, Global NGS Oncology Testing Market is Expected to Reach US$75 Billion

75% CAGR

Screening (~150 Million Tests)

Asymptomatic population at heightened risks

16% CAGR

Therapy Selection (~7 Million Tests)

Population diagnosed with cancer

27% CAGR

Monitoring (~20 Million Tests)

Population monitored for therapeutic response or disease recurrence

INSIGHTA

The Transaction

Transaction Summary

Terms

- Acquisition of 50% of the equity interests in Insighta for total consideration of US$100M, with US$80M in cash and US$20M of shares in Prenetics
- Prof. Dennis Lo to be Chairman of Insighta
- Danny Yeung as CEO of Prenetics and of Insighta

Timing and Closing

- Anticipated to close in July 2023
- Subject to customary closing conditions and regulatory approvals

INSIGHTA▶

Prevention | CircleDNA

At CircleDNA, we recognize that every individual has unique health needs and goals, and we are dedicated to empowering them with the tools and knowledge to take control of their health.

Preventative Health Platform

Longevity

Cancer Prevention

Weight Management

Mental Wellness

Fertility

Organ Health

Kids Health

Gut Health

ePharmacy

Telehealth

Healthcare Network

Genetic Testing

Health Concierge

Home Testing

Supplements

INSIGHTA

Treatment | ACT Genomics

Traditional Medicine

Traditional Medicine: Same Treatment for all

Cancer patient with i.e. colon cancer receive the same therapy, even though they have different biomarkers.

Treatment A

Adverse Effect

No Benefit

Benefit

30% Clinical Response

ACT Genomics

Innovative Medicine: Personalized Medicine

Cancer patient with i.e. colon cancer receive personalized therapy based on their biomarkers.

GENOMICS

Clinical Grade Sequencing

Medical Informatics

Treatment A — 75% Clinical Response

Treatment B — 67% Clinical Response

Treatment C — 67% Clinical Response

INSIGHTA